Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18934268 | 0.85 | TDP1 (0.51) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL4961122 | 0.83 | FDPS (0.43) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL2420469 | 0.83 | FDPS (0.53) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL19737206 | 0.83 | CHRNA7 (0.53) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL7288023 | 0.83 | CHRNA7 (0.53) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL24924148 | 0.83 | FDPS (0.49) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL14732858 | 0.83 | FDPS (0.53) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL14459386 | 0.82 | CHRNB2 (0.52) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL103883 | 0.82 | FDPS (0.55) | CHRNB2CHRNA4TDP1L3MBTL1FDPS | |
| SCHEMBL22857531 | 0.81 | TDP1 (0.56) | CHRNB2CHRNA4TDP1L3MBTL1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0318294-B1 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS (JP) | 1994-12-28 | — | — | EP | claimed |
| EP-0159769-B1 | ELECTROCHEMICAL OXIDATION OF PYRIDINE BASES | REILLY INDUSTRIES, INC. (US) | 1991-03-27 | — | — | EP | claimed |
| EP-0318294-A2 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS CO., LTD (JP) | 1989-05-31 | — | — | EP | claimed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| EP-3686197-B1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH MQ PHARMACEUTICALS LTD (CN) | 2023-06-21 | — | — | EP | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2023-01-31 | — | — | US | disclosed |
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-11382916-B2 | Fused heterotricyclic organic compounds, pharmaceutical compositions, and medical uses thereof | ALEVERE MEDICAL CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021237112-A1 | NOTCH INHIBITORS AND USES THEREOF | STEMSYNERGY THERAPEUTICS, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| WO-2008033460-A2 | TREATING PAIN, DIABETES, AND LIPID METABOLISM DISORDERS | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033456-A1 | SPIRO-CONDENSED AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABILISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-0928792-B1 | Bicyclic(3.1.0)hexanes and related compounds | PFIZER PROD INC (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-0318294-B1 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS (JP) | 1994-12-28 | — | — | EP | disclosed |
| US-5294720-A | Viricides | THE DUPONT MERCK PHARMACEUTICAL CO. (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0532693-A1 | 1,4-DIAMINO-2,3-DIHYDROXYBUTANES | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-03-24 | — | — | EP | disclosed |
| US-5125930-A | Polymeric cationic dyes including a quaternized pyridinium group | NIPPON CHEMICAL WORKS CO., LTD. (JP) | 1992-06-30 | — | — | US | disclosed |
| EP-0318294-A2 | Dimeric and trimeric cationic dyes | NIPPON CHEMICAL WORKS CO., LTD (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-4001257-A | OXIDATION, NITRIC ACID | NIPPON SODA COMPANY LIMITED (JA) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | CHRNB2 1270/4885CHRNA4 3874/4885TDP1 1609/4885 |
| US-11566015-B2 | Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof | MC3R, MC1R, MC2R | CHRNB2 111/4885CHRNA4 311/4885TDP1 4753/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | CHRNB2 4364/4885CHRNA4 4461/4885TDP1 710/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | CHRNB2 4364/4885CHRNA4 4461/4885TDP1 710/4885 |
| US-11382916-B2 | Fused heterotricyclic organic compounds, pharmaceutical compositions, and medical uses thereof | FABP4, HSD17B4, LIPC | CHRNB2 3991/4885CHRNA4 3471/4885TDP1 1153/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | CHRNB2 4364/4885CHRNA4 4461/4885TDP1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.